Simcere Pharmaceutical Opens ‘Hong Kong Collaborative Innovation Center’ Accelerating R&D and Translation of Innovative Drugs
Key Takeaways
- HKSTP will join hands with Simcere to leverage Hong Kong's unmatched connectivity with mainland China, offering a world of opportunities.
- Listed on the HKEX in 2020, Simcere is the first batch of strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) of the HKSAR Government.
- The ‘Hong Kong Collaborative Innovation Center’ will focus on four core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection.
(Hong Kong, 12 December 2023) – Hong Kong Science and Technology Parks Corporation (HKSTP) and Simcere Pharmaceutical Group Limited (Simcere; 2096.HK), today announced the opening of the Simcere ‘Hong Kong Collaborative Innovation Center’ at the Hong Kong Science Park. HKSTP will join hands with Simcere to leverage Hong Kong's scientific research capabilities, talent and global access and further enhance Hong Kong's capabilities in the research and development (R&D) and translation of innovative drugs, contributing to pharmaceutical innovation in the Greater Bay Area (GBA) and the country.
Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP, said, “With Simcere joining us, it will inject impetus into the biomedical industry, offering more collaboration and innovation opportunities. Under the government’s steadfast support, we believe there will be rapid growth in the biomedical industry over the next five years.”
Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group, said, “The Simcere ‘Hong Kong Collaborative Innovation Center’ will leverage Hong Kong's unique advantages in its connection with the GBA, robust scientific research prowess, abundant talent pool and international capital market, backed by strong policy support to accelerate our pipelines in Hong Kong and global market.”
Simcere is an innovation-driven, full-value chain pharmaceutical company. It was listed on the Hong Kong Stock Exchange (HKEX) in 2020 and became the first batch of strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) in October 2023. In addition to Hong Kong, Simcere has also established four innovation centers in Shanghai, Nanjing, Beijing and Boston.
Photo 1: Mr Gordon Cheung, AS for Innovation, Technology and Industry Bureau (fourth from left, first row), Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP (third from left, first row), Dr Grace Lau, Head of Institute for Translational Research of HKSTP (second from left, first row), Professor Lo Yuk Lam, President of HK Bio-Med Innotech Association (HKBMIA) (second from right, first row), Mr Song Ka Woon, Independent Non-Executive Director of Simcere Pharmaceutical Group Limited (fourth from right, first row), and Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group Limited (third from right, first row), were present at the opening ceremony.
Photo 2: Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP, said, “We shall join hands with Simcere and further leverage Hong Kong's strength of ‘bridging the mainland market and embracing global opportunities’.”
Photo 3: Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group, said, “We are looking forward to fostering innovative strategic partnerships between Simcere and academic institutions, industry partners and the Hong Kong government. We aim to facilitate the establishment of a collaborative innovation ecosystem for the pharmaceutical industry across Greater Bay Area and ultimately realises Simcere’s innovation strategy 2.0 of ‘Radiate into global markets with Hong Kong as our anchor point’.”
###
For media enquiries, please contact pr@hkstp.org. Explore our latest news in the PRESS ROOM.